259 related articles for article (PubMed ID: 26033187)
1. Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Huang CY; Chang MC; Huang WY; Huang CT; Tang YC; Huang HD; Kuo KT; Chen CA; Cheng WF
Sci Rep; 2015 Jun; 5():10680. PubMed ID: 26033187
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
3. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
4. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
5. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
7. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA.
He X; Zheng Z; Li J; Ben Q; Liu J; Zhang J; Ji J; Yu B; Chen X; Su L; Zhou L; Liu B; Yuan Y
Carcinogenesis; 2012 Mar; 33(3):555-62. PubMed ID: 22223849
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
9. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma.
Planagumà J; Abal M; Gil-Moreno A; Díaz-Fuertes M; Monge M; García A; Baró T; Xercavins J; Reventós J; Alameda F
J Pathol; 2005 Dec; 207(4):422-9. PubMed ID: 16175655
[TBL] [Abstract][Full Text] [Related]
11. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
12. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
13. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
14. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Tian B; Chen X; Zhang H; Li X; Wang J; Han W; Zhang LY; Fu L; Li Y; Nie C; Zhao Y; Tan X; Wang H; Guan XY; Hong A
Oncotarget; 2017 Jun; 8(26):42300-42313. PubMed ID: 28404945
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of long noncoding RNA, NEAT1 promotes cell proliferation, invasion and migration in endometrial endometrioid adenocarcinoma.
Li Z; Wei D; Yang C; Sun H; Lu T; Kuang D
Biomed Pharmacother; 2016 Dec; 84():244-251. PubMed ID: 27664948
[TBL] [Abstract][Full Text] [Related]
20. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]